Floatz logo

Famitinib

EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor

Sun Yat-sen UniversitySmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor cohort.

Asset / SponsorPhaseRating
Palbociclib
Sun Yat-sen University
Phase 1/2CCC

Same molecule, other indications

Famitinib is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
EGFR Activating MutationDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →